Erratum to: Diabetes Ther (2014) 5(2):355–366 DOI 10.1007/s13300-014-0089-4
In Table 3 on page 358 under the heading Dose modifications for Empagliflozin the sentence “Contraindicated in patients with creatinine clearance <45 ml/min” should read “Stopped in patients with creatinine clearance <45 ml/min”.
Open Access
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s13300-014-0089-4.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Kalra, S. Erratum to: Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology. Diabetes Ther 6, 95 (2015). https://doi.org/10.1007/s13300-015-0095-1
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13300-015-0095-1